Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0039730 (
thalassemia
)
10,305
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Infection is very common in
thalassemia
and is one of the major causes of death. To date, it is not quite clear why these patients are susceptible to infection. In this study, lymphocyte immunophenotyping for CD3(+) (T-cells), CD3(+)CD4(+) (T-helper/inducer cells), CD3(+)CD8(+) (T-suppressor/cytotoxic cells), CD3(-)CD19(+) (B-cells), and CD3(-)CD16/56(+) (natural killer cells) subsets and expression of the activation antigen
CD69
on CD3(+)CD4(+) and CD3(+)CD8(+) T-cells were determined in the whole blood of
thalassemia
patients, using a three-color flow cytometric technique. Results showed that only splenectomized beta-
thalassemia
/hemoglobin (Hb) E patients displayed a marked increase in absolute number of all lymphocytes. In addition, splenectomized beta-
thalassemia
/Hb E showed a significantly lower percentage of CD3(+) cells, with a corresponding increase in CD19(+) cells. These differences, when compared with normal subjects and other
thalassemia
patients, may be attributed to splenectomy. alpha-
thalassemia
patients, on the other hand, showed no significant difference from the normal group. While lymphocyte subsets in splenectomized beta-
thalassemia
/Hb E patients showed an abnormal distribution, T-cell activation in these patients was not different from the activation seen in normal subjects. This implies that
thalassemia
patients, during the steady state of disease, appear to have normal T-lymphocyte function with only moderate abnormalities of T- and B-lymphocyte subsets.
...
PMID:Lymphocyte subsets and specific T-cell immune response in thalassemia. 1067 38